Wire · opportunities
Biomea posts phase 1 data to pitch oral GLP-1 to potential partners, but investors appear ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 14 October 2026 · Fusion42 review
Biomea Fusion released phase 1 data for its oral small molecule GLP-1 drug candidate BMF-650 showing moderate weight loss and favourable gastrointestinal tolerability, but investors reacted negatively, pushing the stock down 30%. The company plans to limit development investment and seek partners for further trials due to financial constraints.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You need to rethink your drug development plans if you are working on oral GLP-1. Biomea’s financial caution and investor scepticism open a door for partnership deals and alternative funding routes faster than full in-house trials.
◆ Coverage
1 source · 14 Oct 2026
◆ Related on Wire
◆ Topics